In order to evaluate the efficacy and side effects of the non-insulin antidiabetes medications as an adjunct treatment in type 1 diabetes mellitus (T1DM), we conducted systematic searches in MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials for randomized controlled trials published between the date of inception and March 2020 to produce a systematic review and meta-analysis. Overall, 57 studies were included. Compared with placebo, antidiabetes agents in adjunct to insulin treatment resulted in significant reduction in glycosylated hemoglobin (weighted mean difference [WMD], –0.30%; 95% confidence interval [CI], –0.34 to –0.25%; P<0.01) and body weight (WMD, –2.15 kg; 95% CI, –2.77 to –1.53 kg; P<0.01), and required a significantly lower dosage of insulin (WMD, –5.17 unit/day; 95% CI, –6.77 to –3.57 unit/day; P<0.01). Compared with placebo, antidiabetes agents in adjunct to insulin treatment increased the risk of hypoglycemia (relative risk [RR], 1.04; 95% CI, 1.01 to 1.08; P=0.02) and gastrointestinal side effects (RR, 1.99; 95% CI, 1.61 to 2.46; P<0.01) in patients with T1DM. Compared with placebo, the use of non-insulin antidiabetes agents in addition to insulin could lead to glycemic improvement, weight control and lower insulin dosage, while they might be associated with increased risks of hypoglycemia and gastrointestinal side effects in patients with T1DM.
Citations
Citations to this article as recorded by
Prescribing patterns of adjunctive therapy for the treatment of type 1 diabetes mellitus among Australian endocrinologists Patrice Forner, Jennifer Snaith, Jerry R. Greenfield Internal Medicine Journal.2024; 54(5): 779. CrossRef
Dioscin: Therapeutic potential for diabetes and complications Haoyang Gao, Ze Wang, Danlin Zhu, Linlin Zhao, Weihua Xiao Biomedicine & Pharmacotherapy.2024; 170: 116051. CrossRef
The Impact of Body Mass Index, Residual Beta Cell Function and Estimated Glucose Disposal Rate on the Development of Double Diabetes and Microvascular Complications in Patients With Type 1 Diabetes Mellitus Rameez Raja Bhagadurshah, Subbiah Eagappan, Raghavan Kasthuri Santharam, Sridhar Subbiah Cureus.2023;[Epub] CrossRef
Type 1 diabetes glycemic management: Insulin therapy, glucose monitoring, and automation Bruce A. Perkins, Jennifer L. Sherr, Chantal Mathieu Science.2021; 373(6554): 522. CrossRef
Current Advances of Artificial Pancreas Systems: A Comprehensive Review of the Clinical Evidence Sun Joon Moon, Inha Jung, Cheol-Young Park Diabetes & Metabolism Journal.2021; 45(6): 813. CrossRef